Illumina (NASDAQ:ILMN - Free Report) had its price target reduced by Scotiabank from $185.00 to $176.00 in a research report report published on Monday morning, Benzinga reports. Scotiabank currently has a sector outperform rating on the life sciences company's stock.
ILMN has been the topic of several other reports. HSBC cut Illumina from a buy rating to a hold rating in a report on Tuesday, January 16th. OTR Global reiterated a mixed rating on shares of Illumina in a report on Wednesday, March 20th. StockNews.com downgraded shares of Illumina from a buy rating to a hold rating in a research report on Friday. Robert W. Baird raised their price target on shares of Illumina from $125.00 to $128.00 and gave the stock a neutral rating in a report on Friday. Finally, Royal Bank of Canada reissued an outperform rating and set a $253.00 price objective on shares of Illumina in a research report on Tuesday, April 9th. Two analysts have rated the stock with a sell rating, eleven have assigned a hold rating and eight have issued a buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of Hold and a consensus target price of $164.65.
Check Out Our Latest Research Report on ILMN
Illumina Stock Performance
Shares of ILMN traded up $1.05 during midday trading on Monday, reaching $118.98. 1,803,169 shares of the stock were exchanged, compared to its average volume of 1,713,389. Illumina has a twelve month low of $89.00 and a twelve month high of $213.91. The company has a quick ratio of 1.36, a current ratio of 1.75 and a debt-to-equity ratio of 0.26. The company has a market cap of $18.95 billion, a P/E ratio of -14.60 and a beta of 1.20. The stock's 50 day simple moving average is $129.67 and its 200 day simple moving average is $127.00.
Illumina (NASDAQ:ILMN - Get Free Report) last posted its earnings results on Thursday, May 2nd. The life sciences company reported $0.09 earnings per share for the quarter, topping analysts' consensus estimates of $0.04 by $0.05. The company had revenue of $1.08 billion during the quarter, compared to the consensus estimate of $1.05 billion. Illumina had a positive return on equity of 2.31% and a negative net margin of 28.71%. The company's revenue was down 1.0% on a year-over-year basis. During the same quarter last year, the firm earned $0.08 earnings per share. On average, sell-side analysts expect that Illumina will post 0.91 earnings per share for the current year.
Insider Transactions at Illumina
In other Illumina news, CEO Jacob Thaysen bought 7,330 shares of the business's stock in a transaction dated Thursday, February 22nd. The shares were purchased at an average price of $135.29 per share, for a total transaction of $991,675.70. Following the purchase, the chief executive officer now directly owns 14,861 shares of the company's stock, valued at $2,010,544.69. The acquisition was disclosed in a legal filing with the SEC, which is available through this link. Company insiders own 0.17% of the company's stock.
Hedge Funds Weigh In On Illumina
Hedge funds and other institutional investors have recently modified their holdings of the business. abrdn plc lifted its stake in Illumina by 764.9% in the fourth quarter. abrdn plc now owns 339,023 shares of the life sciences company's stock valued at $47,206,000 after purchasing an additional 299,827 shares during the last quarter. J.P. Morgan Private Wealth Advisors LLC purchased a new position in Illumina in the third quarter valued at approximately $29,558,000. International Assets Investment Management LLC raised its holdings in Illumina by 210.5% during the 4th quarter. International Assets Investment Management LLC now owns 48,194 shares of the life sciences company's stock valued at $6,711,000 after acquiring an additional 32,672 shares during the period. Aquila Investment Management LLC raised its holdings in Illumina by 150.0% during the 4th quarter. Aquila Investment Management LLC now owns 25,000 shares of the life sciences company's stock valued at $3,481,000 after acquiring an additional 15,000 shares during the period. Finally, Weil Company Inc. raised its holdings in Illumina by 59.2% during the 3rd quarter. Weil Company Inc. now owns 22,963 shares of the life sciences company's stock valued at $3,152,000 after acquiring an additional 8,539 shares during the period. Hedge funds and other institutional investors own 89.42% of the company's stock.
About Illumina
(
Get Free Report)
Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.
See Also
Before you consider Illumina, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Illumina wasn't on the list.
While Illumina currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
